Obermatt
See Similar Stocks →

bioMerieux

PAR:BIM · FR0013280286
Health Care Equipment & SuppliesLarge

360

72
EV / EBIT83
Price / Owner Earnings67
Owner Earnings Yield96
Dividend Yield50
Price/Sales51
EV / Gross Profit83
Price/Book65
Return on Capital77
Cash Return on Capital78
Return on Equity51
EBIT Margin61
Gross Profitability59
Cash Conversion62
Accruals40
Owner Earnings Margin68
Sales growth27
Profit Growth75
Long-Term EPS Growth39
Owner Earnings Growth90
Reinvestment64
Price momentum10
Debt load89
Refinancing69
Debt Payback100
Liquidity94
Analyst ratings20
Opinion Changes26
Price Target Upside74
Market mood82
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

bioMerieux generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryFrance
IndustryHealth Care Equipment & Supplies
SizeLarge
TypePublic Company
ExchangeENXTPA
Founded1967
Employees10,172
Websitebiomerieux.com/fr/fr.html
ISINFR0013280286
Last UpdateApr 2, 2026
Indices
CAC All (France)SBF 120 (France)
Themes
Health DiagnosticsGeneticsBiomedical EngineeringInfectious DiseasesBiotechnologyManufacturing

Description

Analysis

Bargain bin

bioMérieux S.A. falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.

The price is fair. You pay 16.1× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 3% yearly growth; analysts expect 7%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is sturdy. The company scores 16/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
72
2023202420252026

All-time high

100

May 2025

All-time low

72

Jun 2026

Average rank

89

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
51
52
52
72
Price/Earnings
54
40
47
50
Price/Book
65
44
52
61
Dividend Yield
50
47
53
51
Value (overall)
52
70
55
75

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare bioMerieux with its peers
DiaSorin
MIL:DIA
34
CountryItaly
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
Grifols
MCE:GRF
61
CountrySpain
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Stratec
GER:SBS
36
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Medartis Holding
SWX:MED
33
CountrySwitzerland
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Siemens Healthineers
GER:SHL
17
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeX-Large
Full Stock Analysis →
First Sensor
GER:SIS
80
CountryIreland
IndustrySemiconductors & Semiconductor Equipment
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →